A study to see the efficacy of injection vitamin D3 given into the skin warts.

Not yet recruiting

• Conditions: Viral wart, unspecified,

• Registration Number: CTRI/2019/04/018822
• Lead Sponsor: Department of Dermatology

Brief Summary

Verruca vulgaris is caused by different serotypes of HPV and various treatment modalities are available including topical therapies, immunotherapy and surgical options. This is prospective interventional study to know the efficacy of intralesional vitamin D3 in verruca vulgaris which is the primary outcome. Secondary outcomes include to study the adverse effects and recurrence rates.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-06
• Last Update Posted: 2019-04-25

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• All untreated consecutive patients of verruca vulgaris.
• Above the age of 14 years.

Exclusion Criteria

• Pregnant or lactating females.
• Any evidence of immunosuppression including HIV .
• With a prior history of hypersensitivity to Vitamin D.
• History of intake of vitamin D3, anabolic steroids or bisphosphonates in the last 3 months.
• Patients having any significant systemic illness.
• Patients having pre procedure serum vitamin D levels >100 ng/ml.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Therapeutic efficacy of intralesional vitamin D3 in verruca vulgaris	0,1,2,3,8 weeks

Secondary Outcome Measures

Name	Time	Method
Recurrence rate of verruca vulgaris treated with intralesional vitamin D3	8 weeks
Adverse effects of intralesional vitamin D3 in patients of verruca vulgaris.	0,1,2,3,8 weeks

Trial Locations

Locations (1)

Government Medical College and Hospital; 🇮🇳 Chandigarh, CHANDIGARH, India

Government Medical College and Hospital

🇮🇳Chandigarh, CHANDIGARH, India

Dr Surbhi Jain

Principal investigator

9478188115

jain.shubh93@gmail.com